MyMedR

Displaying all 5 publications

Abstract:

Sort:

Fulltext Increasing rate of detection of fusidic acid resistance in methicillin-resistant Staphylococcus aureus isolated from clinical samples in Malaysia

Alreshidi MA, Mariana NS

Med J Malaysia, 2011 Aug;66(3):276.
PMID: 22111461
Fulltext Bioinformatics analysis of rhinovirus capsid proteins VP1-4 sequences for cross-serotype vaccine development

Alshrari AS, Hudu SA, Asdaq SMB, Ali AM, Kin CV, Omar AR, et al.

J Infect Public Health, 2021 Nov;14(11):1603-1611.
PMID: 34624714 DOI: 10.1016/j.jiph.2021.09.001

BACKGROUND: Rhinoviruses (RV) are associated with the development and exacerbations of asthma and chronic obstructive pulmonary disease. They've also been linked to more severe diseases like pneumonia, acute bronchiolitis, croup, and otitis media. Because of the hypervariable sequences in the same serotypes, no effective vaccine against rhinoviruses has been developed to date. With the availability of new full-length genome sequences for all RV-A and RV-B serotyped strains, this study used bioinformatics to find a suitable RV strain with the highest similarity matrices to the other strains.
METHODS: The full genomic sequences of all known different RV-A and -B prototypes were downloaded from the National Centre for Biotechnology Information (NCBI) and divided into minor low-density lipoprotein receptor (LDLR) and major intercellular adhesion molecule groups (ICAM). The sequences were edited using Biological Sequence Alignment Editor, v 7.2.0 (BioEdit software) to study each capsid protein (VP1, VP2, VP3, and VP4) and analyzed using the EMBL-EBI ClustalW server and the more current Clustal Omega tool for the calculation of the identities and similarities.
RESULTS: We analyzed and predicted immunogenic motifs from capsid proteins that are conserved across distinct RV serotypes using a bioinformatics technique. The amino acid sequences of VP3 were found to be the most varied, while VP4 was the most conserved protein among all RV-A and RV-B strains. Among all strains studied, RV-74 demonstrated the highest degree of homology to other strains and could be a potential genetic source for recombinant protein production. Nine highly conserved regions with a minimum length of 9-mers were identified, which could serve as potential immune targets against rhinoviruses.
CONCLUSION: Therefore, bioinformatics analysis conducted in the current study has paved the way for the selection of immunogenic targets. Bioinformatically, the ideal strain's capsid protein is suggested to contain the most common RVs immunogenic sites.
High prevalence of qacA/B carriage among clinical isolates of meticillin-resistant Staphylococcus aureus in Malaysia

Shamsudin MN, Alreshidi MA, Hamat RA, Alshrari AS, Atshan SS, Neela V

J Hosp Infect, 2012 Jul;81(3):206-8.
PMID: 22633074 DOI: 10.1016/j.jhin.2012.04.015

The minimum inhibitory concentrations (MICs) of 60 meticillin-resistant Staphylococcus aureus (MRSA) isolates from Malaysia to three antiseptic agents - benzalkonium chloride (BZT), benzethonium chloride (BAC) and chlorhexidine digluconate (CHG) - were determined. All isolates had MICs ranging from 0.5 to 2 mg/L. Antiseptic resistance genes qacA/B and smr were detected in 83.3% and 1.6% of the isolates, respectively. Carriage of qacA/B correlated with reduced susceptibility to CHG and BAC. This is the first report of the prevalence of qacA/B and smr gene carriage in Malaysian MRSA isolates, with a high frequency of qacA/B carriage. The presence of these antiseptic resistance genes and associated reduced susceptibility to antiseptic agents may have clinical implications.
Genetic variation among methicillin-resistant Staphylococcus aureus isolates from cancer patients in Saudi Arabia

Alreshidi MA, Alsalamah AA, Hamat RA, Neela V, Alshrari AS, Atshan SS, et al.

Eur J Clin Microbiol Infect Dis, 2013 Jun;32(6):755-61.
PMID: 23318757 DOI: 10.1007/s10096-012-1801-9

One hundred and twenty methicillin-resistant Staphylococcus aureus (MRSA) isolated from cancer and non-cancer patients in Saudi Arabia were investigated for antibiotic resistance, virulence determinants and genotypes. The majority of MRSA isolates from cancer (n = 44, 73.3 %) and non-cancer patients (n = 34, 56.7 %) were multi-resistant to more than four classes of antibiotics. Virulence gene profiling showed that all strains were commonly positive for adhesin genes, except ebps and bbp genes, which were not detected in any isolate. Although the presence of adhesin genes varied slightly among MRSA isolates from cancer and non-cancer patients, these variations were not found to be statistically significant. In contrast, the presence of the toxin genes seb, sec, seg and sei was significantly elevated in MRSA strains isolated from cancer patients. Multilocus sequence typing (MLST) detected six and nine sequence types (STs) among isolates from cancer and non-cancer patients, respectively. Using spa typing, 12 and 25 types were detected, including four new types. The ability of different MRSA clones to become multi-resistant and their ability to acquire different virulence factors may contribute to their success as pathogens in individual groups of patients.
Global, Regional, and National Burden of Bone Cancers, 1990 to 2023, With Forecasts to 2050: A Systematic Analysis for the Global Burden of Disease Study 2023

GBD 2023 Bone Cancer Collaborators, Monsereenusorn C, Bisignano C, May ML, Pritchett N, Kocarnik JM, et al.

JAMA Oncol, 2026 Oct 29.
PMID: 42955027 DOI: 10.1001/jamaoncol.2026.4274

IMPORTANCE: Primary bone cancers include multiple histologic types, with survival differing by age and location. Results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 were analyzed to support policies and initiatives worldwide.
OBJECTIVE: To estimate the global burden of bone cancer from 1990 to 2023 and forecast future trends to 2050.
DESIGN, SETTING, AND PARTICIPANTS: This systematic analysis estimated bone cancer incidence, mortality, and disability-adjusted life-years (DALYs) in 204 countries and territories grouped by GBD super-regions and World Bank income groups from 1990 to 2023, with forecasts through 2050. Individuals of all ages with bone cancers included in the GBD 2023 study were included in analyses. Data were analyzed from June 2023 to July 2025.
MAIN OUTCOMES AND MEASURES: The GBD 2023 study used standardized estimation methods to describe bone cancer incidence, mortality, and DALYs in 2023, as well as trends over the past 3 decades and forecasts through 2050. All estimates are presented with 95% uncertainty intervals (UIs), and age-standardized rates (ASRs) were calculated using GBD-specific age weights.
RESULTS: In 2023, there were 111 000 (95% UI, 81 300-164 000) malignant bone cancer cases, 76 600 (95% UI, 60 700-96 300) deaths, and 3.02 million (95% UI, 2.29 million-3.96 million) DALYs globally. A bimodal age distribution was noted in both incidence (peaking at ages 10 to 14 years and 65 to 69 years) and mortality (peaking at ages 15 to 19 years and 65 to 69 years). The highest ASRs for incidence were in Southeast Asia, East Asia, and Oceania (1.6 per 100 000; 95% UI, 1.1-2.4), while Sub-Saharan Africa had the highest ASRs for DALYs (51.0 per 100 000; 95% UI, 27.7-79.7). By World Bank income group, upper-middle-income countries had the highest ASRs for incidence, whereas low-income countries exhibited the highest ASRs for both mortality and DALYs. Globally, incident cases, deaths, and DALYs increased from 1990 to 2023, while global mortality and DALY ASRs were relatively stable; high-income countries experienced a decline in mortality and DALY ASRs. Forecasts suggest a potential increase in global cases and deaths by 2050.
CONCLUSIONS AND RELEVANCE: In this systematic analysis, the burden of bone cancer varied by age, geography, and time, underscoring global disparities. These findings provide valuable insights to inform health system planning and resource allocation tailored to different settings.